title: The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine.
abstract: BACKGROUND
  Early stage gastric cancer diagnosis has ensued different approaches in resection strategies. In order to increase the proportion of cases which have undergone radical resection or have reduced the recurrence rate, different pre-operative treatments have introduced. Here, we have verified an active preoperative chemotherapeutic regimen in locally advanced gastric cancer patients.
  
  
  METHODS
  Forty nine patients who have found eligible to enter this phase 2 trial have treated with oxaliplatin 100 mg/m2 IV, docetaxel 50 mg/m2 IV, plus capecitabine 625 mg/m2 PO (TOX). Clinical staging has been following the first 2 cycles of induction chemotherapy. Patients that have further undergone radical surgery, have evaluated for pathological response rate.
  
  
  RESULTS
  Anemia (10.2%), nausea (10.2%) and vomiting (6.1%) were the most frequent grade 3 or 4 adverse effects. Regarding the pathologic staging, 6 patients (12.2%) had complete response (95% CI 3% to 21.4%), 18 of them (36.7%) had partial response (95% CI 23.2% to 50.2%), then 3 patients (6.1%) had stable disease (95% CI 0%-12.8%). Among the patients who had surgery, 22% had pathologic complete response.
  
  
  CONCLUSIONS
  Preoperative chemotherapeutic regimen of TOX seems to be an active and safe neoadjuvant therapy in non metastatic gastric cancer. It should further be considered with concurrent radiotherapy.
authors.affiliation: Clinical Research Center, Milad Hospital, Tehran, Iran ; Dept. of Radiation Oncology, Fayazbakhsh Hospital, Tehran, Iran.
authors.forename: Seyyed-Hossein
authors.initials: SH
authors.lastname: Yahyazadeh-Jabbari
authors.affiliation: Clinical Research Center, Milad Hospital, Tehran, Iran.
authors.forename: Nasser
authors.initials: N
authors.lastname: Malekpour
authors.affiliation: Clinical Research Center, Milad Hospital, Tehran, Iran ; Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Bahram
authors.initials: B
authors.lastname: Salmanian
authors.affiliation: Dept. of Radiation Oncology, Fayazbakhsh Hospital, Tehran, Iran.
authors.forename: Hossein
authors.initials: H
authors.lastname: Foodazi
authors.affiliation: Clinical Research Center, Milad Hospital, Tehran, Iran ; Dept. of Statistics and Mathematics, School of Health Management and Information Sciences, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Masoud
authors.initials: M
authors.lastname: Salehi
authors.affiliation: Clinical Research Center, Milad Hospital, Tehran, Iran.
authors.forename: Farsad
authors.initials: F
authors.lastname: Noorizadeh
keywords: Chemotherapy; Neoadjuvant Therapy; Preoperative period; Stomach neoplasm